{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigrbklm63xqictnjpgj4xfquhth3xovl523urccwqq2sxxk7b4e74",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mjmddto7ug62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidpidnuxpv343hqsuguuj35em4ktccf56i4hkxxihnul5tikqiv3m"
    },
    "mimeType": "image/jpeg",
    "size": 33618
  },
  "path": "/2026/04/16/travere-therapeutics-kidney-disease-fda-approval/?utm_campaign=rss",
  "publishedAt": "2026-04-16T10:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Adam's Biotech Scorecard",
    "Adam's Take",
    "Biotech",
    "biotechnology",
    "chronic disease",
    "drug development",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "How a rare disease drugmaker won FDA approval after a clinical trial disappointed.",
  "title": "STAT+: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway",
  "updatedAt": "2026-04-15T20:57:19.000Z"
}